Discounted Cash Flow (DCF) Analysis Levered
RedHill Biopharma Ltd. (RDHL)
$2.04
-0.09 (-4.23%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2017 Actual | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
| Revenue | 4.01 | 8.36 | 6.29 | 64.36 | 85.76 | 308.76 | 1,111.67 | 4,002.47 | 14,410.56 | 51,884.03 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (%) | ||||||||||
| Operating Cash Flow | -44.77 | -34.46 | -40.75 | -48.58 | -65.05 | -1,437.94 | -5,177.18 | -18,639.99 | -67,111.74 | -241,630.27 |
| Operating Cash Flow (%) | ||||||||||
| Capital Expenditure | -1.18 | -0.06 | -0.20 | -53.77 | -0.12 | -72.30 | -260.31 | -937.23 | -3,374.42 | -12,149.30 |
| Capital Expenditure (%) | ||||||||||
| Free Cash Flow | -45.95 | -34.52 | -40.95 | -102.35 | -65.16 | -1,510.24 | -5,437.49 | -19,577.22 | -70,486.16 | -253,779.57 |
Weighted Average Cost Of Capital
| Share price | $ 2.04 |
|---|---|
| Beta | 2.150 |
| Diluted Shares Outstanding | 0.03 |
| Cost of Debt | |
| Tax Rate | 0.00 |
| After-tax Cost of Debt | 18.87% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | 13.840 |
| Total Debt | 87.81 |
| Total Equity | 0.06 |
| Total Capital | 87.87 |
| Debt Weighting | 99.93 |
| Equity Weighting | 0.07 |
| Wacc |
Build Up Free Cash Flow
Year A/P | 2017 Actual | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Projected | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected |
| Revenue | 4.01 | 8.36 | 6.29 | 64.36 | 85.76 | 308.76 | 1,111.67 | 4,002.47 | 14,410.56 | 51,884.03 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -44.77 | -34.46 | -40.75 | -48.58 | -65.05 | -1,437.94 | -5,177.18 | -18,639.99 | -67,111.74 | -241,630.27 |
| Capital Expenditure | -1.18 | -0.06 | -0.20 | -53.77 | -0.12 | -72.30 | -260.31 | -937.23 | -3,374.42 | -12,149.30 |
| Free Cash Flow | -45.95 | -34.52 | -40.95 | -102.35 | -65.16 | -1,510.24 | -5,437.49 | -19,577.22 | -70,486.16 | -253,779.57 |
| WACC | ||||||||||
| PV LFCF | -1,270.50 | -3,848.16 | -11,655.59 | -35,303.26 | -106,928.96 | |||||
| SUM PV LFCF | -159,006.47 |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | 18.87 |
| Free cash flow (t + 1) | -258,855.16 |
| Terminal Value | -1,534,411.16 |
| Present Value of Terminal Value | -646,517.73 |
Intrinsic Value
| Enterprise Value | -805,524.19 |
|---|---|
| Net Debt | 58.34 |
| Equity Value | -805,582.53 |
| Shares Outstanding | 0.03 |
| Equity Value Per Share | -27,702,704.66 |